sameAs
P101
Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, Fingolimod will change therapeutic paradigm approachNew developments in the management of psoriasis and psoriatic arthritis: a focus on apremilastProfile of certolizumab and its potential in the treatment of psoriatic arthritisTreatment for primary hypothyroidism: current approaches and future possibilitiesThe use of lorcaserin in the management of obesity: a critical appraisalRosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspectiveSafety and efficacy of azacitidine in myelodysplastic syndromesIdentification of targets and new developments in the treatment of multiple sclerosis--focus on cladribineNew and emerging treatments for symptomatic tardive dyskinesiaInhaled treprostinil: a therapeutic reviewImiglucerase in the treatment of Gaucher disease: a history and perspectiveTreatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gelAvailable and emerging treatments for Parkinson's disease: a reviewCurrent and emerging pharmacological treatments for sarcoidosis: a reviewChanges in CD4+ T-cells and HIV RNA resulting from combination of anti-TB therapy with Dzherelo in TB/HIV dually infected patientsGolimumab in radiographic and nonradiographic axial spondyloarthritis: a review of clinical trialsSecukinumab for rheumatology: development and its potential place in therapyGaleterone for the treatment of advanced prostate cancer: the evidence to dateSitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapySpotlight on grazoprevir-elbasvir once-daily combination and its potential in the treatment of hepatitis CClinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimodReceptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cellsAn appraisal of golimumab in the treatment of severe, active nonradiographic axial spondyloarthritisTafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to dateCeftazidime/avibactam: a novel cephalosporin/nonbeta-lactam beta-lactamase inhibitor for the treatment of complicated urinary tract infections and complicated intra-abdominal infectionsA review of omalizumab for the management of severe asthmaCabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapyResistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive reviewPosition and enforcement practice of the People's Republic of China's pharmaceutical data exclusivity protectionThe arsenal of pathogens and antivirulence therapeutic strategies for disarming themApremilast in the therapy of moderate-to-severe chronic plaque psoriasisCritical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophreniaMolecular mechanisms of cisplatin resistance in cervical cancerSafety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertensionSpotlight on brexpiprazole and its potential in the treatment of schizophrenia and as adjunctive therapy for the treatment of major depressionSpotlight on botulinum toxin and its potential in the treatment of stroke-related spasticityEfficacy and safety of modified-release prednisone in patients with rheumatoid arthritisSpotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectivesThe interplay of post-translational modification and gene therapySelective use of sorafenib in the treatment of thyroid cancer
P1433
Q22305854-327FCC1B-4933-4845-A472-306BA2D938F1Q22305855-29C502C0-37B0-4272-BA47-7FC86CB79784Q22305856-6FE0AB48-9887-4B2C-8C1E-CF8956BDF23FQ22305857-C933B56B-B63D-40C4-AC66-5A7AB0994772Q24594774-F57978AD-7618-4D55-9387-B36A8470049AQ24594814-9744A1EB-DFF7-40BE-ADD8-3366CFB389D9Q24596561-58914D06-4D96-4A15-919A-FAFB0B44CF0FQ24597369-316C38A2-91C9-44D8-ADE1-4FFE836B7605Q24599912-930D02CE-D410-4E3D-9E66-8998904B18AAQ24601864-7BEA401C-BBB4-4E4D-B5B5-6DB4EF10983AQ24631426-BEE46F83-05B3-4D0A-B594-3689F982F945Q24632899-26340F7F-1969-4B7A-AB7C-3BDE817A3C77Q24633444-8B461E99-89D1-41E3-AB7C-7200E5C301C3Q24633717-B35AADE4-1A1A-4C25-9D6D-2EA2C238FE88Q24653869-289A9F74-9489-4F8A-9886-02C13FC81E08Q26738520-3ED7D695-3287-41B0-A042-E1EE1DAECC6DQ26738523-56327E29-4112-4C55-B19F-D8526EAB2F77Q26739887-BEFA01A6-3321-4092-99FC-AFB369CF2111Q26739888-64407D5A-D0B6-451D-9522-D01BFC419CDFQ26740233-C081AEB1-C05F-4F6B-8C17-DFF5D4DD7287Q26740235-29B67972-3346-40E3-ADA7-425053C97143Q26740953-1812AB09-2C43-4B80-8A95-35D4433447A3Q26741170-EA202186-DB7A-4D50-991E-E9257D5AEEE7Q26741307-07DA488C-A7FA-4D27-B1EE-D53BA56D2BC3Q26741312-B16B8732-12C3-4E18-8A55-8B6BE4FAE327Q26741315-177BF0B8-751B-4EF6-813D-35B404092AD0Q26741450-143CE517-722F-4D90-AB66-784E702A30ADQ26744068-47197F23-7F02-4D1B-8065-9043BC4FF416Q26744367-EBA6C416-F48A-4E21-8349-8CC8A3A39987Q26745604-23FD784C-9D95-47D8-A02B-321369EE56ADQ26745789-5CD37438-3B03-46C6-A7D3-F7755783AB1FQ26745792-FB55A73F-3E48-4362-A7C0-F7BFDE8B5C39Q26746228-A9F7D443-C323-4D49-AA51-346F52E8CF92Q26747812-329F3177-5830-48D4-B88B-82D1A4716587Q26747833-89185204-6E2D-4043-A93B-68CDD8DC3890Q26750450-D3E62259-C369-49DF-B1A8-0706D4909C46Q26750454-8DD4E62C-F468-4F7E-B920-272C9A3FE86CQ26751274-A8860F8E-3CB7-4940-9B37-90005B22E30AQ26751281-31A1077D-53CC-4950-BBBF-315EE3AF151DQ26752891-DB07223A-8325-4EF4-B596-1F4703E07398
P1433
description
begutachtete wissenschaftliche Zeitschrift
@de
czasopismo naukowe
@pl
peer-reviewed scientific journal
@en
revista científica
@es
rivista scientifica
@it
vědecký časopis
@cs
wetenschappelijk tijdschrift
@nl
рецензований науковий журнал
@uk
वैज्ञानिक पत्रिका
@hi
英语期刊
@zh
name
Drug Design, Development and Therapy
@ast
Drug Design, Development and Therapy
@de
Drug Design, Development and Therapy
@en
Drug Design, Development and Therapy
@es
Drug Design, Development and Therapy
@it
Drug Design, Development and Therapy
@nl
type
label
Drug Design, Development and Therapy
@ast
Drug Design, Development and Therapy
@de
Drug Design, Development and Therapy
@en
Drug Design, Development and Therapy
@es
Drug Design, Development and Therapy
@it
Drug Design, Development and Therapy
@nl
prefLabel
Drug Design, Development and Therapy
@ast
Drug Design, Development and Therapy
@de
Drug Design, Development and Therapy
@en
Drug Design, Development and Therapy
@es
Drug Design, Development and Therapy
@it
Drug Design, Development and Therapy
@nl
P31
P243
P3181
P1055
P1058
P1156
19700175230
P1160
Drug Des. Dev. Ther.
P1277
P1476
Drug Design, Development and Therapy
@en
P236
P243
P3181
P407
P5115
P571
2007-01-01T00:00:00Z